Read-Gene S.A. (WSE: RDG)

Poland flag Poland · Delayed Price · Currency is PLN
4.960
0.00 (0.00%)
Jan 20, 2025, 10:45 AM CET
-19.35%
Market Cap 58.95M
Revenue (ttm) 12.67M
Net Income (ttm) -455.44K
Shares Out 11.79M
EPS (ttm) -0.04
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,055
Average Volume 351
Open 4.960
Previous Close 4.960
Day's Range 4.960 - 5.120
52-Week Range 4.000 - 6.660
Beta -1.02
RSI 56.95
Earnings Date Feb 10, 2025

About Read-Gene

Read-Gene S.A. engages in the detection, prevention, and treatment of various types of cancer. Its activities include chemoprevention, clinical tests, and genetic tests. Chemoprevention is the use of natural or synthetic substances to stop, reverse, or delay the process of developing cancer. The company conducts clinical trials in cancer patients; and provides genetic tests and genetic-oncological consultations to all patients for the most common cancers, such as breast, ovary, prostate, stomach, large intestine, and breast cancer. Read-Gene S.... [Read more]

Industry Biotechnology & Medical Research
Sector Healthcare
Founded 2005
Employees 29
Stock Exchange Warsaw Stock Exchange
Ticker Symbol RDG
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.